Tercica Increlex Hypoglycemia Risk Mitigated By Dose Timing, Titration - FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Growth therapy merited labeling precaution but not rejection of NDA, as sought by competitor Insmed in citizen petition, FDA review documents state.
You may also be interested in...
Tercica’s Growth Treatment Increlex Clears FDA With Orphan Drug Exclusivity
The company plans to launch the extreme short stature therapy in January with a 30-member sales force.
Mobile Health Apps Could Disrupt Medical Technology Market– Report
Ernst & Young annual report highlights the importance of emerging “patient-empowering” and “information-leveraging” technologies, and their power to drive health care efficiencies.
Mobile Health Apps Could Disrupt Medical Technology Market– Report
Ernst & Young annual report highlights the importance of emerging “patient-empowering” and “information-leveraging” technologies, and their power to drive health care efficiencies.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: